{"task_id": "97680add935447f8", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 262/464)", "text": "e or drug intolerance)\nTuberculosis: Pulmonary\n251\n\n--- Page 273 ---\nTREATMENT ISSUES\nVACCINATION\nWITH\nBCG\n(Bacillus\nCalmette\nGuerin)\ndecreases miliary and meningeal TB by\n75 86% and pulmonary TB by 50% in children. How\never, BCG leads to false positive skin test, which may\ncompromise contact tracing and decision to treat\nlatent TB infection\nDIRECTLY OBSERVED TREATMENT\nmost effective\nmethod to prevent multi drug resistant tuberculosis\naccording to the WHO\nMEDICATION DETAILS\n\u0002\nRIFAMPIN (RIF)\nbactericidal. Side effects include\nhepatic toxicity (less than INH, but induces hepatic\nmicrosomal enzymes ! \" clearance and # effects\nof many drugs), flu like symptoms, red orange\nurine, sweat, tears\n\u0002\nISONIAZID (INH)\nbactericidal and inexpensive.\nSide effects include hepatitis (\" with increased\nage and alcohol use), peripheral neuropathy\n(# with pyridoxine 10 mg PO daily or 25 mg PO\ndaily if HIV, diabetes, malnourished, renal failure,\npregnancy, or breast feeding)\n\u0002\nPYRAZINAMIDE (PZA)\nbactericidal at acidic pH in\ncells. Side effects include GI intolerance, hepatic\nTREATMENT ISSUES (CONT\u2019D)\ninjury, hyperuricemia due to # renal excretion,\narthraligias\n\u0002\nETHAMBUTOL\nmostly bacteriostatic. Main side\neffect is optic neuritis\nDRUG MONITORING\n\u0002\nBASELINE\nplatelet, Cr, AST, ALP, bilirubin, uric acid\n(pyrazinamide), visual acuity, and red green color\ndiscrimination (ethambutol)\n\u0002\nFOLLOW-UP\nsymptoms\nof\nhepatotoxicity\nand\nvisual disturbance\nTREATMENT OF CO INFECTION WITH TB AND\nHIV\nsimilar treatment outcome with or without\nHIV, but treatment of active TB infection in HIV\npatients should be extended beyond 6 months if\nbacteriologic or clinical response is slow or subopti\nmal. Also beware of TB and HIV drug interactions\n(protease inhibitors and non nucleoside reverse tran\nscriptase inhibitors may cause toxic levels of rifampin,\nwhich should be replaced by rifabutin)\nCANADIAN\nTUBERCULOSIS\nSTANDARDS\nsee\nhttp://www.phac aspc.gc.ca/tbpc latb/index\neng.php for more information\nApproach to Gram Stain, Culture, and Sensitivity\nGRAM POSITIVE COCCI\nCLUSTERS (catalase positive) (Staphylococci)\n\u0002\nCOAGULASE POSITIVE\nS. aureus\n\u0002\nCOAGULASE NEGATIVE\nS. epidermidis, S. saprophyti\ncus, S. hominis, S. lugdunesis, S. schleiferi\nPAIRS/CHAINS (catalase negative)\n\u0002 a-HEMOLYTIC STREPTOCOCCI\nS. pneumoniae, viri\ndians group streptococci, enterococcus (Group D\nstrep)\n\u0002 b-HEMOLYTIC STREPTOCOCCI\nS. pyogenes (Group A\nstrep), S. agalactiae (Group B strep), group C, F, G\nstrep\n\u0002\nOTHERS\nAbiotrophia, Granulicatella (\u2018\u2018nutrient var\niant Strep\u2019), Leuconostoc, Lactococcus, Aerococcus\nANAEROBIC\nPeptostreptococcus,\nStreptococcus,\nPeptococcus, Anaerococcus\nGRAM POSITIVE BACILLI\nACID FAST (mycobacterium)\nM. tuberculosis, M.\nleprae, M. avium intracellulare complex, or non tuber\nculous Mycobacteria (NTM, also known as mycobac\nteria other than TB (MOTT)). These organisms have\nGram positive type cell walls, but do not stain Gram\npositive due to the waxy mycolic acids in the cell\nenvelope\nGRAM POSITIVE BACILLI (CONT\u2019D)\nSPORE FORMING\n\u0002\nAEROBIC\nBacillus anthrax, Bacillus cereus\n\u0002\nANAEROBIC\nClostridium perfringens, C. difficile,\nC. botulinum\nNON SPORE FORMING\n\u0002\nAEROBIC, FACULTATIVE, AEROTOLERANT\nCorynebac\nterium/diphtheroids, Lactobacillus, Listeria, Garden\nerella, Nocardia\n\u0002\nANAEROBIC\nActinomyces,\nPropionibacterium,\nEubacterium\nBRANCHING BACILLI\nwABCD LMNw Actinomyces\n(acid fast negative), Bacillus, Clostridium, Diphtheroids,\nListeria, Lactobacillus, Mycobacterium (Modified and\nZiehl Neelsen acid fast), Nocardia (modified acid fast)\nGRAM NEGATIVE COCCI\nNEISSERIA\nN. meningitidis (diplococci), N. gonor\nrhoeae (diplococci), other Neisseria\nMORAXELLA\nM. catarrhalis\nGRAM NEGATIVE BACILLI\nAEROBIC\n\u0002\nGLUCOSE FERMENTING AND LACTOSE FERMENTING\na\nnumber of Enterobacteriaceae including E. coli,\nCitrobacter, Enterobacter, Klebsiella, Serratia\n252\nApproach to Gram Stain, Culture, and Sensitivity", "text_length": 3880, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 262/464)", "type": "chunk", "chunk_index": 261, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.607768", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.608711", "status": "complete", "chunks_added": 2}